Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study

(2012) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

(2011) C. M. Kelly et al.   ANNALS OF ONCOLOGY

Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

(2011) M. J. Rodrigues et al.   ANNALS OF ONCOLOGY

The prognostic significance of lymphovascular invasion in invasive breast carcinoma

(2011) Emad A. Rakha et al.   CANCER

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

(2011) Heather L. McArthur et al.   CANCER

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Treatment in T1ab, Node-Negative, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Carcinomas

(2010) Manuel Jorge Rodrigues et al.   JOURNAL OF CLINICAL ONCOLOGY

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

(2009) Yeon Hee Park et al.   BREAST CANCER RESEARCH AND TREATMENT

Refining Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy

(2009) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommandations pour la pratique clinique, Nice, Saint-Paul-de-Vence: et de trois !

(2009) J. Gligorov et al.   Oncologie

Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies

(2008) R.H.H. Groenwold et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY